6OKQ

Crystal structure of the SF12 Fab

Summary for 6OKQ

• Entry DOI: 10.2210/pdb6okq/pdb
• Descriptor: SF12 Fab Heavy Chain,SF12 Fab Heavy Chain, SF12 Fab Light Chain,SF12 Fab Light Chain (2 entities in total)
• Functional Keywords: hiv-1 broadly-neutralizing antibody, fab structure, silent face, envelope, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 6
• Total formula weight: 147792.54

Authors

Barnes, C.O.,Bjorkman, P.J. (deposition date: 2019-04-14, release date: 2019-06-05, Last modification date: 2024-11-13)

Primary citation

Schoofs, T.,Barnes, C.O.,Suh-Toma, N.,Golijanin, J.,Schommers, P.,Gruell, H.,West Jr., A.P.,Bach, F.,Lee, Y.E.,Nogueira, L.,Georgiev, I.S.,Bailer, R.T.,Czartoski, J.,Mascola, J.R.,Seaman, M.S.,McElrath, M.J.,Doria-Rose, N.A.,Klein, F.,Nussenzweig, M.C.,Bjorkman, P.J.
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Immunity, 50:1513-, 2019

PubMed Abstract: Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3Å cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448 glycan. Effective bNAbs can therefore be raised against HIV-1 Env's silent face, suggesting their potential for HIV-1 prevention, therapy, and vaccine development.

PubMed: 31126879
DOI: 10.1016/j.immuni.2019.04.014

Experimental method

X-RAY DIFFRACTION (3.2 Å)